New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
05:27 EDTGSK, AGENGlaxo's Phase 3 Malaria Vaccine Candidate with Agenus' QS-21 shows efficacy
Agenus (AGEN) announced the second complete set of results from the Phase 3 trial of GlaxoSmithKline's (GSK) RTS,S malaria vaccine candidate -- also known as Mosquirix -- which contains Agenus' QS-21 Stimulon adjuvant, were published online in the New England Journal of Medicine and announced at the International Vaccines for Africa Conference in Cape Town, South Africa. QS-21 Stimulon is a component of AS01, one of GSK's proprietary adjuvant systems used in RTS,S. The Phase 3 study met its primary endpoint and demonstrates statistically significant protection against clinical and severe malaria in infants. Agenus is entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
News For AGEN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
17:31 EDTGSKRadius Health hires Dr. Lorraine Fitzpatrick as Chief Medical Officer
Radius Health (RDUS) announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline (GSK), responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
July 24, 2015
05:04 EDTAGEN, GSKAgenus reports GSK Malaria vaccine receives positive opinion from CHMP of EMA
Subscribe for More Information
July 23, 2015
07:14 EDTAGENAgenus reports Q2 EPS (53c), consensus (15c)
Subscribe for More Information
July 20, 2015
07:02 EDTAGENAgenus acquires novel antibodies to immuno-oncology target CEACAM1
Subscribe for More Information
July 16, 2015
08:03 EDTGSKGlaxoSmithKline expects to ship 32M-38M flu vaccines over 2015-16 season
Subscribe for More Information
July 15, 2015
05:57 EDTGSKGlaxoSmithKline, Francis Crick Institute to collaborate on range of new drugs
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use